TTK and uterine cancer: Here, to validate the biological relevance of the overlap between gene dependency, drug response, and mass spectrometry proteomics data, we tested the effect of BAY1217389, a TTK inhibitor recently tested in a Phase I clinical trial for the treatment of solid tumors [45, 46], on uterine cancer cell line viability in vitro.